Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_assertion type Assertion NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_head.
- NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_assertion description "[We aimed to validate the impact of GSTT1 and GSTM1 deletions and of the GSTP1Ile105Val polymorphism on outcome and toxicity in 140 patients with advanced Hodgkin's lymphoma enrolled in the prospective multicenter HD2000-GISL trial, comparing ABVD, BEACOPP and CEC regimens.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_provenance.
- NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_assertion evidence source_evidence_literature NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_provenance.
- NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_assertion SIO_000772 21916526 NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_provenance.
- NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_assertion wasDerivedFrom befree-20140225 NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_provenance.
- NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_assertion wasGeneratedBy ECO_0000203 NP432982.RAEkLKIZOJCtmBNCiq3_reFBDXHr56a6Hwf6RMg7es7ko130_provenance.